Mina Abdiannia

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study”.

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Cancer & Metabolism(2023)10.1186/s40170-023-00306-2

N/A

0.947DataRank · unranked

30 citations

Kian‐Huat Lim, J. L. Volkman, Mina Abdiannia, Hannah Johnston, Zack Nigogosyan +13 more

Phase I dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4146

N/A

0DataRank · unranked

1 citations

Kian-Huat Lim, Robert R. McWilliams, Rama Suresh, A. Craig Lockhart, Amberly Brown +15 more